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Abstract (299/300 words) 
Objective: To determine whether, in children with newly diagnosed Type 1 diabetes 
who were not acutely unwell, management at home for initiation of insulin treatment 
and education of the child and family, would result in improved clinical and 
psychological outcomes at two years post-diagnosis.  
Design: A multicentre randomised controlled trial (Jan 2008/Oct 2013) 
Setting: Eight paediatric diabetes centres in England, Wales and Northern Ireland 
Participants: 203 clinically-well children aged under 17 years, with newly diagnosed 
Type1 diabetes and their carers 
Intervention: Management of the initiation period from diagnosis at home, for a 
minimum of three days, to include at least six supervised injections and delivery of 
pragmatic educational care. 
Main outcome measures: Primary outcome was glycosylated haemoglobin (HbA1c) 
concentration at 24 months post-diagnosis. Secondary outcomes included coping, 
anxiety, quality of life and use of NHS resources. 
Results: 203 children, newly diagnosed, were randomised to commence 
management at home (n=101) or in hospital (n=102). At the 24 month primary end 
point, there was one withdrawal and a follow-up rate of 194/202 (96%). Mean HbA1c 
in the home treatment arm was 72.1mmol/mol and in the hospital treated arm 72.6 
mmol/mol. There was a negligible difference between the mean HbA1c levels in the 
two arms adjusted for baseline (1.01, 95% CI 0.93 to 1.09). There were mostly no 
differences in secondary outcomes at 24 months, apart from better child self-esteem 
in the home-arm. 
No home-arm children were admitted to hospital during initiation and there were no 
adverse events at that time. The number of investigations was higher in hospital 
patients during the follow-up period. There were no differences in insulin regimens 
between the two arms.  
Conclusions: There is no evidence of a difference between home- and hospital- 
based initiation of care in children newly diagnosed with type 1 diabetes across 
relevant outcomes. 
 
Trial Registration: ISRCTN reference number: ISRCTN78114042 
 
Article Summary 
Strengths and limitations of this study 
• The largest multicentre randomised controlled trial to test the effectiveness of 
home or hospital initiation of treatment of children newly diagnosed with Type 
1 diabetes 
• The only adequately powered trial to test effectiveness of the location of care 
at diagnosis of Type 1 diabetes in childhood 
• Inclusion of both teaching and district general hospitals, in England, Wales 
and Northern Ireland 
• Pragmatic approach to the clinical and educational care delivered during the 
initiation period to reflect differences in practice 
• There was a change in practice regarding insulin regimes in participating 
centres during the course of the trial 
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Introduction 
 
The initial management of childhood-onset Type 1 diabetes (T1D) is invasive and 
complex, requiring extensive support from diagnosis. Optimal blood glucose control is 
essential to minimize risk of life-changing complications but is difficult to achieve, 
placing young people at an unacceptably high risk of developing micro- and 
macrovascular complications in later life.1 In addition, the emotional cost of T1D to the 
individual is significant, and a substantial long-term adverse psychological response 
to a diagnosis of T1D in childhood is reported in both children and parents/carers, 
particularly mothers.2 Although parents experience a grief response to diagnosis 
similar to that associated with bereavement, they report positive experiences of having 
their child managed at home from diagnosis,3 allowing them to deal with situations that 
occurred within the framework of their everyday lives. The relative normality of this 
helped them feel more ‘in control’ of the situation, enabling them to cope more 
effectively and feel less anxious. 
 
There is a global trend to move clinical care from hospital into the community, reflecting 
concerns about healthcare costs, limited availability of hospital beds and the need to 
promote more integrated healthcare delivery to improve the quality and patient 
experience of care.4,5 However, community-based services are not necessarily 
cheaper than hospital care in the short term, and any particular model or initiative 
needs evaluation of transferability and adaptability into a specific healthcare system, 
safety, cost effectiveness and acceptability to patients and their families. 
 
There is little agreement worldwide about where best to manage young people at 
diagnosis with practices varying from minimal hospitalisation with largely out-patient-
based management in the UK, USA and Australia to admission for several weeks in 
Europe and Japan.6–8  Although hospitalisation is necessary if children are severely 
dehydrated or ketoacidotic, over half are relatively well at diagnosis, do not require 
intravenous therapy, and stabilisation at diagnosis may not require hospitalisation. 
7,9,10 It has been claimed that home management is a safe, effective alternative to 
hospitalisation at diagnosis3,9,11–14 but studies evaluating hospitalisation or home 
management at diagnosis are limited by their often retrospective nature and lack of 
power.6,15 A systematic review concluded that studies in this area were generally of 
low quality. It suggested that home-based management at diagnosis does not lead to 
disadvantaged metabolic control or other adverse outcomes and there was no 
difference in overall costs. A large well-designed randomised controlled trial was 
therefore required to investigate whether there are significant differences in short and 
long-term outcomes between the two approaches.6 
 
We hypothesised that children who had their initial treatment and education managed 
at home would have better clinical and psychological outcomes than those managed 
in hospital. The aim of The Delivering Early Care in Diabetes Evaluation (DECIDE) 
trial therefore, was to investigate over two years from diagnosis, the effect of initiating 
treatment at home or in hospital by assessing and comparing glycaemic control, in 
children with type 1 diabetes aged under 17 years and to assess use of NHS resources 
during the initiation (days 0-3 after diagnosis) and subsequent follow-up periods. Cost-
effectiveness and cost consequences analyses will be reported separately. 
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Methods 
 
A full description of the trial methods has been published16 and can be accessed at 
http://www.biomedcentral.com/1471-2431/11/7. In brief, this was an individually 
randomised controlled trial at eight UK paediatric diabetes centres (n=8) in NHS 
secondary care in England, Northern Ireland and Wales. Participating centres were 
Belfast, Cambridge, Cardiff, Hull, Liverpool, Newcastle, Nottingham and 
Southampton. Criteria for centre selection included a minimum of 30 newly diagnosed 
children per year and geographical placement to try and achieve diversity in socio-
economic parameters across included sites. Each centre comprised at least one 
consultant paediatrician with an interest in diabetes, a paediatric diabetes nurse, and 
a paediatric dietitian in addition to other multidisciplinary team members. 
 
 
Participants 
Children and their carers were eligible to participate if the child was aged <17 years, 
newly diagnosed with T1D and if the child and parent/carer were able to complete 
study materials and give informed assent (child aged 8-12 years) and consent/assent 
(parent/carer and child aged 13–17 years). 
 
Exclusion criteria were: 
• ketoacidosis requiring intravenous fluids and insulin 
• children requiring hospitalisation for reasons other than their diagnosis of T1D 
• a coexisting chronic disorder (e.g. cystic fibrosis) that would impact independently 
but significantly on blood glucose control 
• a diagnosis of type 2 diabetes or Maturity Onset Diabetes of the Young (MODY) 
• an uncertain diagnosis 
• a sibling with T1D 
• children who were to begin treatment on a continuous subcutaneous insulin 
infusion (CSII) 
• children under the care of the local authority 
• children whose home circumstances were deemed unsuitable for home 
management. 
 
 
Sample size and recruitment To have 80% power to detect an effect size of 0.4 
(difference in mean HbA1c of 5mmol/mol with an SD of 14mmol/mol6) at a 5% 
significance level), 200 participants were required. To allow for loss to follow up of 
17%, a target of 240 participants was set for recruitment. A previous study in Canada 
which evaluated reducing the amount of in-patient time at diagnosis showed a 
difference of 7.65mmol/mol in mean HbA1c at two years.9 Within each centre, a trial 
specific DECIDE research nurse was employed to co-ordinate nursing management 
of participants and data collection. Participants were recruited by paediatric diabetes 
team members or DECIDE research nurses. Participants (aged over eight years) and 
all parents/carers of participants (aged <17 years) were given information about the 
trial to read whilst in the assessment unit/paediatric ward. They had time to consider 
participating in the trial while blood tests were taken to confirm the clinical diagnosis.  
 
Randomisation and masking 
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Once informed consent/assent was obtained, participants were randomised to hospital 
management or home management using an automated telephone system 
operational 24 hours a day. Randomisation was computer generated and stratified by 
centre and balanced using randomly chosen permuted blocks. The randomisation ratio 
was 1:1. It was not possible to blind participants and those delivering the intervention. 
However, the blood samples collected for the primary outcome of HbA1c were 
analysed blind to study group. 
 
Intervention 
Home management 
Home management was defined as involving no overnight stay in hospital. Standard 
elements of home management common to all participating centres were: 
• discharge home on the day of diagnosis with no overnight admission to hospital 
• all subsequent treatment, face to face education about diabetes and its 
management by nursing staff and emotional/practical support was to be delivered 
at home or on an out-patient basis. Out-patient visits were defined as attending 
ward/clinic for no longer than two hours for supervision of injections as necessary 
according to local need, for a minimum of three days (the initiation period); this time 
frame provided uniformity across the two trial arms 
• dietetic education at home or as an out-patient 
• early team review to reflect on the team’s experience of home-based care and to 
address identified problems 
 
Hospital management 
Children randomised to the hospital arm were admitted at diagnosis, with an intended 
minimum stay of three nights during the initiation period. During their inpatient stay, 
families received treatment and education similar in nature to that received by those 
in the home-based arm and multidisciplinary support in the ward environment 
consistent with local practice. 
 
Home and hospital management 
Each participating centre was provided with one research grant-funded DECIDE Study 
nurse for the duration of the trial. They were trained, where needed, to provide 
diabetes care by the local diabetes teams, as well as having access to support from 
the lead centre (Cardiff), as required. How the DECIDE research nurse was integrated 
into the team varied between centres for logistical reasons. In some centres, provision 
of education and support to newly diagnosed participants and their families in both 
study arms was shared equally with other paediatric diabetes team members, whereas 
in others, the DECIDE research nurses undertook all the home management. 
 
As a pragmatic, randomised controlled trial allowing for different approaches to 
providing clinical care, participating centres were not given specific, detailed 
instructions of what should be delivered in terms of diabetes education and support. 
Families in both arms received written information about diabetes and diabetes 
education as routinely delivered by individual centres. Centres were asked to provide 
the same education programme to the newly diagnosed and their families, regardless 
of location of initial care and no attempt was made to influence their normal 
approaches. Children were advised on personalised insulin dose changes dependent 
on the results of blood glucose testing, with the aim of optimising glycaemic control as 
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soon as possible after diagnosis. To facilitate delivery of the trial, a DECIDE manual 
was provided to all centres, offering guidance in key areas such as initial diagnosis, 
recruitment, home management and hospital management. The manual 
recommended:  
• that the insulin regime should be determined by local practice but suggested a 
starting dose of approximately 0.5U/kg/d adjusted flexibly in light of individual 
response. 
• a minimum of four capillary glucose checks daily and a target range of blood 
glucose concentrations of 4-9mmol/l. 
 
All families were given an appointment to attend the next appropriate diabetes clinic, 
received continued support from health professionals through telephone contact and 
clinic visits, and were able to access help and advice out of office hours. Thereafter, 
participants randomised to both arms received outpatient appointments in line with 
local practice and individual need. 
 
 
Outcomes 
The primary outcome was children’s glycaemic control (HbA1c analysed at a central 
laboratory) 24 months post-diagnosis when most participants would have no 
significant endogenous insulin secretion, thus providing an effective measure of 
diabetes management. 
 
Secondary outcomes concerning participants were HbA1c at three and 12 months 
post-diagnosis (analysed at a central laboratory) and questionnaire-based 
psychological assessment of quality of life ((KINDL-R)17 and PedsQL 3.0 Diabetes 
Module18, issues in coping with T1D19) and diabetes knowledge20 at one, 12 and 24 
months. Secondary outcomes concerning parent(s)/carers were anxiety,21 issues in 
coping with T1D,22 quality of life ((KINDL-R)17 and PedsQL 3.0 Diabetes Module18) 
and diabetes knowledge20 at one, 12 and 24 months. The impacts on social activities 
and independence were measured using a bespoke questionnaire developed for this 
trial, which will be reported separately. All questionnaires were self-completed where 
possible in those aged eight years and over at trial entry to ensure independent 
answers from children and their parents. To monitor safety, numbers of serious 
adverse events (SAEs) per participant were collected. Growth (height, weight and 
BMI) was measured at baseline, three, 12 and 24 months. NHS resource use for the 
initiation period (days 0-3) and for the follow-up period to 24 months, and days off work 
and school in the initiation period were also documented. 
 
Resource use 
The intervention did not require additional training for existing healthcare teams over 
and above the DECIDE manual for guidance about home- and hospital-based care for 
those not previously experienced in providing either model of care. Data on NHS 
resource use were collected, which covered initiation plus the full period of follow-up 
at three, 12 and 24 months. 
 
Statistical analysis 
The primary analysis followed intention to treat principles for the complete case data 
set. Comparison of mean HbA1c between the two arms at the 24 month follow-up time 
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point was carried out including baseline HbA1c as a covariate. HbA1c data were 
transformed to normality using a natural log transformation. The difference between 
arms in HbA1c, the intervention effect, is therefore interpreted as percentage 
difference. This analysis was corrected for any clustering of outcomes within centres 
by using a mixed 2-level hierarchical linear model. 
 
Repeated measures secondary analysis of the primary outcome using a generalised 
linear model was carried out using the three, 12 and 24 month data with baseline data 
as a covariate. This, and the primary analysis, were repeated as sensitivity analyses 
with missing laboratory data replaced by available routine trial site HbA1c 
measurements taken at the relevant timepoints. Where laboratory HbA1c data were 
reported in percentages, data were converted to mmol/mol using the equation 
[mmol/mol] = 10.93*[%] – 23.5.23 
 
Secondary questionnaire outcomes analyses (except diabetes knowledge) compared 
the two arms using a mixed model at one and 24 months, and assessed repeated 
measures across one, 12 and 24 months through a generalised linear model. These 
analyses also corrected for any clustering of outcomes within centre by using 2-level 
hierarchical versions of these models. Diabetes knowledge, and days off work and 
school were compared using the Mann-Whitney test.  Secondary growth outcomes 
analyses compared the two arms using a mixed model at 24 months, and assessed 
repeated measures across one, 12 and 24 months through a generalised linear model, 
all with Baseline data as a covariate. These analyses also corrected for any clustering 
of outcomes within centre by using 2-level hierarchical versions of these models. 
 
p-values are to be interpreted with caution given the number of statistical tests 
undertaken here (n = 213). Only p<0.001 can be considered statistically significant for 
all following analyses. 
 
Qualitative analysis 
The burden of the trial and a process evaluation was assessed through qualitative 
interviews of young people and their families24 and healthcare professional 
participants (awaiting publication). 
 
Trial governance 
Multicentre approval was granted by Research Ethics Committee for Wales 
(07/MRE09/59). Site-specific approval was granted by participating Acute Trust 
Research and Development Departments. The trial sponsor was Cardiff University.  
 
Patient and public involvement 
Two parents of children diagnosed with T1D were involved in the initial design of the 
DECIDE trial. One of these parents was a co-applicant on the funding application and 
was instrumental in ensuring that the trial was informed by the families’ experience. 
She also attended the ethics committee meeting to provide a service user perspective 
of the value of the trial to inform the committee’s decision. She and another parent 
were part of the Trial Management Group which met monthly and provided input on 
the conduct of the trial throughout. 
 
A dissemination day for the public and clinical staff from all the centres was arranged 
at the end of the trial, at which preliminary results were presented and their implications 
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discussed with lay participants. A newsletter summarising results was also sent to all 
participants for their information. Discussions from the dissemination day helped to 
shape this paper. 
 
 
Results 
 
Two hundred and three children aged <17 years newly diagnosed with T1D and their 
parents/carers, were recruited over 40 months from July 2008 to October 2011 to 
either hospital (n=102) or home management (n=101) (Figure 1). There were 
reasonable similarities across the two arms on important baseline characteristics 
including age, gender and the number of parents/carers (Table 1). 
Table 1: Baseline characteristics of participants by arm and in total 
  
Arm 
Total 
Home 
(n= 101) 
Hospital 
(n = 102) 
n 
Mean (SD) or 
% n Mean (SD) or % n 
Mean (SD) 
or % 
        
HbA1c (mmol/mol) 101 114.8 (32.4) 101 117.6 (33.7) 202 116.2 (33.0) 
        
       
BMI Standard Deviation Score 
(SDS) 
94 
-0.023 
(1.4986) 
97 -0.206 (1.6026) 191 
-0.116 
(1.5509) 
       
Age in years 101 10.0 (3.5) 102 9.6 (3.8) 203 9.8 (3.6) 
        
Gender 
Male 55 54.5 54 52.9 109 53.7 
Female 46 45.5 48 47.1 94 46.3 
        
Parent/carer 
status 
1 Parent/carer 22 21.8 15 14.7 37 18.2 
2 
Parents/carers 
79 78.2 87 85.3 166 81.8 
        
Sibling status 
Zero 14 13.9 20 19.6 34 16.7 
1 or more 87 86.1 82 80.4 169 83.3 
        
Ethnicity 
White 93 92.0 90 88.3 183 90.1 
Black 1 1.0 3 2.9 4 2.0 
Asian 2 2.0 3 2.9 5 2.5 
Chinese 0 0.0 0 0.0 0 0.0 
Mixed 2 2.0 4 3.9 6 3.0 
Other 2 2.0 1 1.0 3 1.5 
Unstated 0 0.0 0 0.0 0 0.0 
 Missing 1 1.0 1 1.0 2 1.0 
        
Presenting 
Symptoms 
Polyuria 97 96.0 100 98.0 197 97.0 
Polydipsia 97 96.0 100 98.0 197 97.0 
Weight Loss 67 66.3 73 71.6 140 69.0 
Lethargy 60 59.4 68 66.7 128 63.1 
Other 28 27.7 12 11.8 40 19.7 
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There was no difference (p=0.863) in the primary outcome of mean HbA1c at 24 
months (controlling for HbA1c at baseline and clustering within centres) between initial 
management at home (72.1mmol/mol) and hospital (72.6mmol/mol) (Table 2). 
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Table 2: Primary outcome – HbA1c at 24 months by Arm controlling for HbA1c at Baseline 
Outcome 
Home Hospital  
n 
Baseline 24 Months 
n 
Baseline 24 Months Differen
ce in 
Means 95% CI p-value Mean SD Mean SD Mean SD Mean SD 
HbA1c (mmol/mol) 98 113.7 31.8 72.1 21.7 95a 115.9 32.5 72.6 21.9 1.01 0.93 to 1.09 0.863 
bHbA1c (mmol/mol) 100 114.3 32.1 71.9 21.56 98 116.9 33.5 72.8 22.0 1.01 0.93 to 1.09 0.858 
Model covariate is natural log transformation of Baseline HbA1c. Reference category is Hospital. Effect/95% CI are back-transformed from a natural log transformation and 
hence are on the ratio level. aOf the 96 patients in the Hospital arm with HbA1c recorded at 24 months, baseline HbA1c was missing for one. bThis result is a sensitivity 
analysis including replaced HbA1c values.
12 
 
This was unchanged in the secondary repeated measures analysis, and in sensitivity 
analyses (in which 14 of the 22 missing HbA1c values across all time points were 
replaced with trial site measurements), with no differences between arms seen. Both 
repeated measures analyses indicated that participants had significantly lower 
(p<0.001) HbA1c at 3 months (home: mean (63.7mmol/mol), median (62.0 
mmol/mol); hospital: mean (62.5mmol/mol), median (61.0mmol/mol) compared to 24 
months (Figure 2). 
While the primary analysis focussed on the final 24 month time point, the secondary 
outcomes were collected at 1 month and 12 month interim time points. Hence repeated 
measures analysis have been performed and presented in full in the following tables 
(Tables 3, 4 & 5).  Here the main effects of trial arm are given along with the effect at 
the interim time periods. The final columns provide the interaction of arm with time and 
significant effects here indicate a differential effect of the intervention over time 
between arms. For children, there was one differential effect over time between trial 
arms which was self-esteem at 1 month (p<0.001) (Table 3). The children in the 
hospital arm had higher self-esteem than those in the home arm at the 1 month time 
point, with the opposite being the case at the 24 month time point.  
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Table 3: Secondary Outcomes from Child Questionnaires – Repeated Measures 
Outcome 
n Arm (reference is Hospital) 
Visit (reference is 24 Months) Visit-Arm interaction (reference is Home by 24 Months) 
1 Month 12 Months 1 Month 12 Months 
1/12/24 
month 
Differe
nce in 
Means 95% CI 
p-
value 
Differe
nce in 
Means 95% CI 
p-
value 
Differe
nce in 
Means 95% CI 
p-
value 
Differ
ence 
in 
Mean
s 95% CI p-value 
Differ
ence 
in 
Mean
s 95% CI 
p-
value 
                 
PedsQL 3.0 Diabetes Module 1 3                 
  Symptoms 131/123/120 -1.5 -6.2 to 3.2 0.519 -0.7 -5.1 to 3.6 0.741 -2.9 -6.5 to 0.7 0.115 -1.0 -6.7 to 4.7 0.727 2.2 -2.3 to 6.8 0.337 
  Barriers 132/123/120 0.1 -6.9 to 7.1 0.982 1.3 -4.0 to 6.7 0.621 -1.3 -6.1 to 3.5 0.593 -1.9 -9.4 to 5.5 0.614 0.1 -6.4 to 6.7 0.969 
  Adherence 131/125/119 -3.9  -9.7 to 1.8 0.180 2.2 -1.9 to 6.4 0.294 -1.6 -5.1 to 2.0 0.390 0.6 -5.6 to 6.9 0.838 2.0 -3.4 to 7.4 0.465 
  Worry 131/124/120 2.6 
-5.2 to 
10.3 
0.520 3.9 
-2.8 to 
10.7 
0.252 1.5 -3.6 to 6.6 0.560 -4.6 -13.8 to 4.6 0.328 2.8 -4.2 to 9.8 0.438 
  Communication 131/124/120 -4.0 
-12.2 to 
4.2 
0.337 2.9 -3.6 to 9.4 0.386 0.1 -6.0 to 6.3 0.968 -3.2 -12.0 to 5.6 0.477 -1.5 -10.1 to 7.1 0.732 
                 
KINDL-R 1 3                 
  Physical Well-being 130/125/120 -1.7 -7.6 to 4.2 0.569 -0.9 -6.3 to 4.6 0.749 -3.1 -8.0 to 1.8 0.211 -5.8 -13.8 to 2.2 0.155 4.4 -2.4 to 11.1 0.205 
  Emotional Well-being 129/125/120 -1.6 -7.1 to 3.8 0.559 -6.3 -5.6 to 4.4 0.805 0.9 -2.8 to 4.6 0.647 -0.8 -8.1 to 6.5 0.831 1.1 -4.8 to 6.9 0.724 
  Self-esteem 129/124/120 7.9 
1.1 to 
14.6 
0.022 8.3 
2.4 to 
14.2 
0.006 2.4 -2.6 to 7.4 0.344 -17.9 -26.7 to -9.1 <0.001 -7.1 
-14.1 to -
0.0 
0.050 
  Family 130/124/119 1.7 -4.8 to 8.1 0.612 2.4 -3.0 to 7.9 0.381 -1.4 -6.6 to 3.9 0.608 -5.8 -12.9 to 1.2 0.105 -0.0 -6.5 to 6.5 0.994 
  Friends 128/124/118 2.2 -3.7 to 8.2 0.463 2.5 -2.2 to 7.1 0.295 -0.3 -4.9 to 4.3 0.901 -1.9 -8.0 to 4.2 0.550 2.5 -3.8 to 8.8 0.434 
  School 125/122/117 4.1 
-2.1 to 
10.4 
0.195 6.6 
1.2 to 
12.1 
0.017 -2.2 -6.3 to 2.0 0.308 -5.6 -13.3 to 2.1 0.157 0.9 -5.7 to 7.5 0.799 
  Total 128/124/119 2.3 -1.8 to 6.5 0.274 3.2 -0.4 to 6.8 0.078 -0.4 -3.1 to 2.4 0.799 -6.5 -11.3 to -1.7 0.008 -0.1 -3.9 to 3.8 0.966 
  Diabetes 130/124/120 1.0 -5.3 to 7.3 0.761 0.9 -3.6 to 5.4 0.694 -0.2 -4.4 to 4.0 0.925 -6.5 -13.0 to -0.1 0.048 -3.0 -9.0 to 3.0 0.326 
                 
Issues in Coping with IDDM 2 4 5                 
  Difficult 129/124/115 -0.1 -0.3 to 0.1 0.373 -0.1 -0.2 to 0.1 0.312 -0.1 -0.2 to 0.1 0.376 -0.0 -0.2 to 0.2 0.948 -0.0 -0.2 to 0.2 0.869 
  Upset 129/124/115 0.0 -0.2 to 0.2 0.939 -0.0 -0.2 to 0.1 0.690 -0.1 
-0.2 to -
0.0 
0.046 0.1 -0.3 to 0.1 0.392 0.1 -0.1 to 0.3 0.361 
                 
Notes: 1 Parent answers about Child, 2 Parents answers about themselves, 3 Higher score is better, 4 Lower score is better, 5 Effect and 95% CI are on Square Root scale 
following a transformation to normalise the distribution
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Table 4: Secondary Outcomes from Child Questionnaires – Comparison at 1 Month. 
Outcome 
Home Hospital 
n 
1 Month 
n 
1 Month Differe
nce in 
Means 95% CI 
p-
value Mean SD Mean SD 
PedsQL 3.0 Diabetes Module 1 3          
  Symptoms 69 60.2 14.23 62 62.3 13.09 -2.1 -6.8 to 2.6 0.384 
  Barriers 69 73.5 18.61 63 75.5 14.73 -2.0 -7.9 to 3.8 0.490 
  Adherence 68 81.6 13.80 63 84.8 11.22 -3.2 -7.6 to 1.1 0.146 
  Worry 68 72.7 24.26 63 74.7 22.94 -2.1 -10.2 to 6.1 0.616 
  Communication 68 72.9 28.01 63 81.3 18.25 -8.4 -16.7 to -0.2 0.045 
          
KINDL-R 1 3          
  Physical Well-being 68 63.0 20.38 62 70.4 19.07 -7.5 -14.3 to -0.6 0.033 
  Emotional Well-being 68 75.5 17.98 61 77.6 15.31 -2.2 -8.0 to 3.7 0.464 
  Self-esteem 68 53.9 24.19 61 64.1 21.22 -10.4 -18.3 to -2.4 0.011 
  Family 69 76.0 17.61 61 79.7 18.10 -3.7 -9.9 to 2.5 0.242 
  Friends 68 79.3 14.62 60 78.6 16.33 0.5 -4.8 to 5.9 0.849 
  School 65 67.0 21.92 60 68.1 18.65 -1.1 -8.3 to 6.1 0.763 
  Total 67 69.2 13.78 61 73.2 12.45 -3.9 -8.6 to 0.7 0.092 
  Diabetes 68 72.2 19.16 62 77.9 15.76 -5.7 -11.7 to 0.4 0.068 
          
Issues in Coping with IDDM 2 4 
5 
         
  Difficult 67 17.6 3.53 62 16.7 3.20 -0.1 -0.2 to 0.0 0.148 
  Upset 67 16.5 4.70 62 15.6 3.96 -0.1 -0.3 to 0.1 0.271 
          
Notes: Reference category is Hospital. 1 Parent answers about Child, 2 Parents answers about themselves, 3 
Higher score is better, 4 Lower score is better, 5 Effect and 95% CI are on Square Root scale following a 
transformation to normalise the distribution
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Table 5: Secondary Outcomes from Child Questionnaires – Comparison at 24 Months 
Outcome 
Home Hospital   
n 
24 Months 
n 
24 Months Differ
ence 
in 
Mean
s 95% CI 
p-
value 
Me
an SD Mean SD 
PedsQL 3.0 Diabetes Module1          
  Symptoms 62 62.0 12.56 58 63.3 14.11 -1.2 -5.9 to 3.6 0.633 
  Barriers 62 74.4 19.21 58 74.2 20.75 0.1 -7.1 to 7.3 0.975 
  Adherence 61 79.0 18.17 58 83.4 14.88 -4.4 -10.5 to 1.6 0.151 
  Worry 62 73.3 20.75 58 71.1 23.74 2.1 -5.9 to 10.2 0.601 
  Communication 62 72.8 25.83 58 78.2 21.22 -5.5 -14.0 to 3.0 0.200 
          
KINDL-R 1          
  Physical Well-being 62 70.0 17.64 58 71.0 15.90 -1.0 -7.1 to 5.1 0.741 
  Emotional Well-being 62 76.6 18.18 58 78.6 12.35 -2.0 -7.7 to 3.6 0.482 
  Self-esteem 62 63.4 19.92 58 56.1 18.71 7.2 0.2 to 14.2 0.043 
  Family 61 79.3 17.81 58 77.9 19.15 1.5 -5.1 to 8.2 0.654 
  Friends 60 79.5 17.03 58 77.4 16.81 2.1 -4.1 to 8.2 0.507 
  School 60 65.9 17.32 57 61.5 18.14 4.6 -1.9 to 11.0 0.163 
  Total 61 72.6 12.77 58 70.4 11.42 2.3 -2.1 to 6.7 0.308 
  Diabetes 62 76.8 18.55 58 76.5 18.07 0.3 -6.3 to 6.9 0.931 
          
Issues in Coping with IDDM 2 3          
  Difficult 59 17.2 4.94 56 16.3 4.44 -0.1 -0.3 to 0.1 0.199 
  Upset 59 15.5 5.03 56 15.6 4.54 0.0 -0.2 to 0.2 0.897 
Notes: Reference category is Hospital. 1 Higher score is better, 2 Lower score is better, 3 Effect and 95% CI are 
on Square Root scale following a transformation to normalise the distribution 
 
 
There were no differences between trial arms in secondary outcomes for parents at 
one month (Table 6), nor at 24 months (Table 7), which is mirrored in the repeated 
measures analyses (Table 8). 
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Table 6: Secondary Outcomes from Parent Questionnaires – Comparison at 1 Month. 
Outcome 
Home Hospital 
n 
1 Month 
n 
1 Month Differ
ence 
in 
Mean
s 95% CI 
p-
value Mean SD Mean SD 
PedsQL 3.0 Diabetes Module 1 3          
  Symptoms 94 56.3 13.67 94 57.0 14.73 -0.7 -4.3 to 3.3 0.715 
  Barriers 94 65.7 17.71 89 65.6 16.38 0.0 -4.9 to 5.0 0.992 
  Adherence 92 76.8 15.41 90 78.8 16.02 -2.0 -6.6 to 2.6 0.382 
  Worry 88 66.2 22.52 87 67.5 25.23 -1.3 -8.4 to 5.8 0.712 
  Communication 90 67.2 27.73 84 74.6 23.78 -7.4 -15.1 to 0.3 0.058 
          
KINDL-R 1 3          
  Physical Well-being 93 63.5 22.01 92 64.8 20.93 -1.5 -7.6 to 4.6 0.627 
  Emotional Well-being 92 73.8 18.72 91 75.1 16.82 -1.3 -6.5 to 3.9 0.612 
  Self-esteem 93 60.3 20.47 91 61.5 19.54 -1.2 -7.0 to 4.6 0.688 
  Family 92 73.5 15.72 90 69.8 17.24 3.7 -1.1 to 8.5 0.131 
  Friends 89 74.1 15.54 92 76.1 14.55 -2.0 -6.4 to 2.4 0.378 
  School 76 74.5 19.51 78 73.5 19.59 1.0 -5.3 to 7.2 0.758 
  Total 88 69.9 13.88 86 70.2 13.00 -0.2 -4.2 to 3.8 0.914 
  Diabetes 89 74.9 17.97 80 75.6 14.54 -0.7 -5.7 to 4.3 0.774 
          
Issues in Coping with IDDM 2 4 5          
  Difficult 90 28.1 8.05 93 28.3 8.94 0.0 -0.2 to 0.2 0.947 
  Upset 91 48.1 14.35 91 49.0 15.55 0.0 -0.3 to 0.4 0.769 
          
Spielberger Short-form Anxiety 2 4 89 16.3 4.55 86 16.7 4.29 0.4 -0.9 to 1.7 0.568 
          
Notes: Reference category is Hospital. 1 Parent answers about Child, 2 Parents answers about themselves, 3 
Higher score is better, 4 Lower score is better, 5 Effect and 95% CI are on Square Root scale following a 
transformation to normalise the distribution
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Table 7: Secondary Outcomes from Parent Questionnaires – Comparison at 24 Months 
Outcome 
Home Hospital   
n 
24 Months 
n 
24 Months Differ
ence 
in 
Mean
s 95% CI 
p-
value Mean SD 
Me
an SD 
PedsQL 3.0 Diabetes 
Module 1 3 
         
  Symptoms 85 59.1 12.80 87 57.2 14.45 2.0 -2.1 to 6.1 0.708 
  Barriers 85 67.3 19.11 86 63.7 20.82 3.6 -2.4 to 9.7 0.238 
  Adherence 84 76.4 17.10 86 76.9 16.92 -0.5 -5.7 to 4.6 0.844 
  Worry 83 70.2 20.58 85 70.6 22.00 -0.4 -6.9 to 6.1 0.901 
  Communication 79 69.7 26.26 82 73.3 21.82 -3.5 -11.1 to 4.0 0.352 
          
KINDL-R 1 3          
  Physical Well-being 85 70.3 17.81 86 65.9 19.07 4.4 -1.2 to 9.9 0.123 
  Emotional Well-being 84 76.2 16.12 87 76.3 14.58 -0.1 -4.7 to 4.6 0.982 
  Self-esteem 85 64.0 14.46 87 61.9 16.77 2.1 -2.6 to 6.8 0.377 
  Family 84 70.9 15.54 86 67.8 17.72 3.2 -1.8 to 8.2 0.213 
  Friends 83 77.0 15.12 88 75.6 14.89 1.4 -3.1 to 5.9 0.545 
  School 81 75.2 17.25 80 72.1 18.1 3.1 -2.4 to 8.6 0.270 
  Total 83 72.1 11.27 87 70.1 11.86 2.1 -1.4 to 5.6 0.244 
  Diabetes 84 77.9 14.95 86 75.8 15.66 2.1 -2.5 to 6.8 0.363 
          
Issues in Coping with IDDM 
2 4 5 
         
  Difficult 83 25.9 8.79 88 26.8 9.20 0.1 -0.2 to 0.3 0.539 
  Upset 84 45.5 17.10 87 47.9 17.53 0.2 -0.2 to 0.5 0.358 
          
Spielberger Short-form 
Anxiety 2 4 
84 14.8 4.65 81 15.1 4.95 -0.3 -1.8 to 1.2 0.701 
          
Notes: Reference category is Hospital. 1 Parent answers about Child, 2 Parents answers about themselves, 3 
Higher score is better, 4 Lower score is better, Effect and 95% CI are on Square Root scale following a 
transformation to normalise the distribution 
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Table 8: Secondary Outcomes from Parent Questionnaires – Repeated Measures 
Outcome 
n Arm (reference is Hospital) 
Visit (reference is 24 Months) Visit-Arm interaction (reference is Home by 24 Months) 
1 Month 12 Months 1 Month 12 Months 
1/12/24 
month Effect 95% CI 
p-
value Effect 95% CI 
p-
value Effect 95% CI 
p-
value Effect 95% CI 
p-
value Effect 95% CI 
p-
value 
PedsQL 3.0 Diabetes 
Module 1 3 
    
            
  Symptoms 188/174/172 0.5 -3.5 to 4.5 0.797 -0.8 -3.8 to 2.2 0.590 -0.5 -2.8 to 1.9 0.590 -1.1 -5.3 to 3.1 0.612 -0.2 -3.6 to 3.1 0.895 
  Barriers 183/174/171 2.7 -3.2 to 8.5 0.367 1.5 -3.0 to 6.1 0.516 1.3 -2.6 to 5.1 0.516 -2.2 -8.4 to 3.9 0.473 -3.1 -8.4 to 2.2 0.248 
  Adherence 182/174/170 -0.3 -5.3 to 4.7 0.903 1.8 -2.1 to 5.6 0.376 -0.9 -4.6 to 2.7 0.615 -1.0 -6.1 to 4.0 0.695 -0.0 -4.7 to 4.6 0.989 
  Worry 176/169/168 -1.1 -7.4 to 5.3 0.740 -2.3 -8.2 to 3.6 0.447 -2.7 -7.5 to 2.2 0.280 -0.6 -8.3 to 7.2 0.886 3.1 -3.5 to 9.6 0.358 
  Communication 174/165/161 -2.9 
-10.2 to 
4.4 
0.437 1.0 -4.6 to 6.5 0.733 -3.8 -9.3 to 1.6 0.167 -2.8 
-11.4 to 
5.7 
0.520 2.9 
-4.9 to 
10.7 
0.470 
                 
KINDL-R 1 3                 
  Physical Well-being 185/176/171 3.9 -1.5 to 9.3 0.162 -1.5 -6.8 to 3.8 0.568 2.2 -1.8 to 6.2 0.280 -5.3 
-12.5 to 
2.0 
0.157 -4.4 -9.8 to 1.0 0.112 
  Emotional Well-being 183/173/171 0.3 -4.2 to 4.8 0.901 -0.6 -4.1 to 2.9 0.729 0.7 -2.3 to 3.6 0.668 -1.6 -7.0 to 3.7 0.549 0.3 -4.1 to 4.7 0.902 
  Self-esteem 184/175/172 1.7 -2.9 to 6.3 0.470 -0.6 -4.6 to 3.3 0.758 -1.0 -4.5 to 2.5 0.573 -2.5 -8.5 to 3.6 0.424 0.3 -4.5 to 5.1 0.916 
  Family 182/174/170 2.9 -1.9 to 7.8 0.233 1.7 -2.2 to 5.5 0.394 0.5 -2.4 to 3.5 0.731 0.9 -3.9 to 5.8 0.705 -3.2 -7.4 to 0.9 0.125 
  Friends 181/174/171 1.2 -3.3 to 5.6 0.607 0.6 -2.9 to 4.2 0.721 -1.6 -4.9 to 1.6 0.329 -3.4 -8.5 to 1.8 0.200 -1.0 -5.6 to 3.6 0.677 
  School 154/161/161 3.0 -2.3 to 8.3 0.263 2.6 -1.7 to 6.9 0.239 1.2 -2.6 to 5.0 0.542 -2.1 -7.9 to 3.7 0.475 2.5 -7.3 to 2.4 0.323 
  Total 174/174/170 1.8 -1.6 to 5.2 0.297 0.1 -2.5 to 2.7 0.936 0.3 -1.7 to 2.3 0.796 -2.0 -5.8 to 1.8 0.312 -1.7 -4.5 to 1.1 0.233 
  Diabetes 169/167/170 1.7 -2.9 to 6.2 0.472 -0.4 -4.1 to 3.2 0.829 1.1 -2.2 to 4.4 0.508 -2.1 -7.3 to 3.2 0.437 -2.5 -7.2 to 2.1 0.284 
                 
Issues in Coping with 
IDDM 2 4 5 
                
  Difficult 183/172/171 0.0 -0.2 to 0.3 0.854 -0.1 -0.3 to 0.0 0.074 -0.0 -0.2 to 0.1 0.472 0.0 -0.2 to 0.2 0.965 0.0 -0.2 to 0.2 0.775 
  Upset 182/170/171 0.1 -0.3 to 0.4 0.696 -0.1 -0.4 to 0.1 0.229 -0.1 -0.3 to 0.1 0.456 -0.0 -0.3 to 0.3 0.894 0.0 -0.2 to 0.3 0.736 
                 
Spielberger Short-form 
Anxiety 2 4 
175/164/165 0.2 -1.2 to 1.6 0.756 -1.5 -2.3 to -0.6 0.001 0.4 -0.5 to 1.2 0.412 0.0 -1.2 to 1.3 0.944 -0.1 -1.3 to 1.2 0.903 
                 
Notes: 1 Parent answers about Child, 2 Parents answers about themselves, 3 Higher score is better, 4 Lower score is better, 5 Effect and 95% CI are on Square Root scale 
following a transformation to normalise the distribution
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For additional tables relating to both child and parent/carer secondary outcomes, see 
Supplementary material, Tables 1 - 6. 
 
For growth outcomes, there were no differences between arms at 24 months or when 
viewed at repeated measures across 3, 12 and 24 months. For height and weight, 
measurements at 3 and 12 months were significantly less than those at 24 months, 
with no evidence of excess weight gain in either arm (Supplementary material Tables 
7 and 8). 
 
The initiation period for this study was the first 3 days. Since in the hospital arm the 
patients were already admitted, no SAEs relating to hospitalisation could be recorded. 
No children in the home arm were admitted to hospital from the home arm during the 
initiation period and there were no adverse events at that time. SAE data were also 
collected during the 2 year follow-up in both arms and more SAEs were reported in 
participants managed in the home arm (Supplementary material, Table 9).  95% 
confidence intervals for the difference in proportion of patients reporting SAEs and 
total events reported are also given in the table and none indicate significant 
differences in SAE rates between arms. For further information the SAEs were 
categorised as diabetes associated or not, most SAE events were hypo- or hyper-
glycaemic events (Supplementary material Table10). 
 
NHS resource use costing data source and unit cost is shown in Supplementary 
material, Table 11 with median use of NHS resources shown in Supplementary 
material, Table 12. Almost all participants in the hospital management group spent the 
prescribed three nights in hospital (Supplementary material, Table 13). No participants 
in the home management group were admitted to hospital during the initiation period. 
There were fewer contacts (Supplementary material, Table 12) with consultants 
(median 1 versus 2) and junior doctors (median 1 versus 3) in the home management 
group. Face to face contacts with diabetes nurses were similar between groups 
(median 6 for both groups) but non face-to-face contacts were higher for the home 
management group (median 2 versus 0), as were miles travelled by the diabetes 
nurses (median 40.3 versus 0.0 miles). Contacts with dietitians were similar between 
groups. During the follow-up period, resource use was similar between groups. There 
was no difference between trial arms during the initiation period in the time that parents 
needed to take off work or the child off school (Supplementary material, Table 14). 
 
Discussion 
 
This multicentre individually randomised trial demonstrates that clinical and 
educational care for newly diagnosed children with T1D whether delivered at home or 
in hospital has no effect on blood glucose control, psychological outcomes or SAEs. 
Both models of care seem acceptable to young people and their families.24 There was 
a change in the balance of who delivered care with a greater focus on nurse delivery 
in the home arm than in hospital, where care was shared more between professional 
groupings. These findings are important as they provide an evidence base for clinical 
practice that to date has been largely informed by clinical anecdote. Our findings 
challenge established clinical practice, as well as inform those responsible for the 
provision of health services who wish to redesign care pathways with more care 
provided in the community. 
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This is the largest randomised trial in any country examining the effect of location of 
clinical and educational care at diagnosis for children with T1D. By including both 
tertiary and secondary care hospitals and a representative sample of young people 
with newly diagnosed T1D, we believe that the findings of this trial may be considered 
generalizable across a range of healthcare systems. The prospective nature of this 
trial and randomisation within centres ensured that potential recruitment bias was kept 
to a minimum. The trial had high follow-up rates and therefore will have unbiased 
estimates of treatment effects. We also used a central laboratory for HbA1c assays 
thereby reducing between site variation in results.25 
 
As most participating centres had no prior experience of home care from diagnosis, 
careful consideration was given to defining and manualising key components of home 
and hospital care, to provide inexperienced centres with adequate guidelines and to 
ensure reproducibility of the intervention. This intervention was informed by a 
comprehensive multidisciplinary research team with input from experts in paediatric 
diabetes medicine, nursing, psychology and complex trials as well as parents of 
children with T1D and was deemed acceptable by young people and families.24  
 
Limitations 
 
Research-funded nurses were employed in the participating centres. This extra 
resource, alongside uncertainties about its impact, may limit the extrapolation from the 
findings of this trial to routine clinical practice as it is possible that home-care may 
prove unfeasible without additional specialist nursing resources. It may be that a hybrid 
model, of a brief stay in hospital and early home management, offers a pragmatic 
solution to the challenges presented by both systems as has been tested in Canada, 
Sweden and Australia.9,26,27 
 
Methodological limitations of our trial included the unblindable nature of the 
intervention and the potential risk of practice in one arm influencing delivery of the 
other arm. Also, we recruited 203 subjects rather than the 240 originally intended 
which was to allow for drop-out and a final sample of 200 to give the trial adequate 
power. However, through a high rate of follow-up, only one subject dropped out and 
194 individuals provided HbA1c samples to measure our primary outcome. It is 
unlikely that obtaining samples from six additional subjects would have altered our 
statistical findings. 
 
Context within current literature 
 
In 2007, a Cochrane Systematic Review6 concluded there were insufficient data to 
determine whether home or out-patient management of children newly diagnosed with 
T1D but not acutely unwell was as good as, or better than, in-patient care. Worldwide, 
we have identified only four randomised controlled trials, in Finland, Canada, Sweden 
and Australia, all of which tested hybrid models, involving short periods (2 – 9 days) 
of inpatient care. None of these trials have shown any clinically important differences 
in outcomes.9,15,26–28   
 
DECIDE is the only multicentre, randomised controlled trial world-wide that has 
achieved an adequate sample to provide statistical power. An important difference 
from previously published studies9,15,26–28 is that no participants in the home arm of 
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this trial were admitted to hospital overnight at diagnosis or were admitted to hospital 
during initiation of treatment. Our finding of no difference in longer term metabolic 
outcome or major quality of life measures is consistent with the findings of these 
other trials as well as recent non-randomised studies and suggests that even 
relatively early discharge does not produce adverse outcomes across a range of 
services in a UK setting.29 Furthermore, the similarity of findings across countries 
with differing models of healthcare and diabetes metabolic outcomes suggest that 
where care is delivered after diagnosis is less important than the quantity and quality 
of the support provided to families. 
Implications for clinical practice 
In England, changes have occurred since completion of this trial in the commissioning 
and delivery of services for children with diabetes, with a greater focus on education 
and a more aggressive approach to insulin therapy30 at diagnosis than has traditionally 
been the case.31,32  This means that if the principles of this trial were to be rolled out 
in clinical practice in a UK-setting, some updating of the home-based intervention 
would be required. This would need to include analyses to identify the key components 
of these more intensive packages of care, to determine how they could be realistically 
incorporated into a home-based model of care in a safe, economic and clinically-
effective way, given that prolonged hospitalisation for several weeks education in a 
UK setting is probably unaffordable. Hybrid models of care as evaluated in Sweden, 
Canada and Western Australia9,26,27 that include a short initial period of hospitalisation 
may prove necessary to incorporate ideal principles from both models of care. 
 
Conclusions 
 
The findings of this trial suggest that there is no evidence of a difference between 
home- and hospital- based initiation of care to children newly diagnosed with T1D 
across relevant outcomes. Given that hospitalisation at diagnosis is costly for the NHS, 
consideration should be given as to how the currently more intensive packages of care 
that are offered to the newly diagnosed might be provided in the context of early 
discharge to home-based care. 
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Figure 1: Participant Flow Diagram 
Figure 2: Median and interquartile ranges of HbA1c at each follow-up visit 
 
